Tixagevimab
Tixagevimab (AZD8895) is a human monoclonal antibody that targets the SARS-CoV-2 receptor binding domain (RBD) . It exhibits neutralizing activity against SARS-CoV-2 by binding to the RBD and the S-glycoprotein ectodomain and blocking S-glycoprotein-mediated binding to the receptor[1].
Product Specifications
CAS Number
[2420564-02-7]
Product Name Alternative
AZD8895; COV2-2196
UNSPSC
12352203
Target
SARS-CoV
Type
Inhibitory Antibodies
Related Pathways
Anti-infection
Applications
COVID-19-anti-virus
Field of Research
Infection
Assay Protocol
https://www.medchemexpress.com/tixagevimab.html
Purity
99.05
Solubility
10 mM in DMSO
Smiles
[Tixagevimab]
Molecular Weight
(146.48 kDa)
References & Citations
[1]Jinhui Dong, et al. Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail. Nat Microbiol. 2021 Oct;6 (10) :1233-1244.|[2]Jean-Sélim DRIOUICH, et al. Activity of Tixagevimab/Cilgavimab against the Omicron variant of SARS-CoV-2 in a hamster model.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Launched
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS1234717-01 0.02 mg (E-Coli)
Recombinant Actinobacillus pleuropneumoniae serotype 7 Acetyl-coenzyme A carboxylase carboxyl transferase subunit alpha (accA)
Ask
View Details MBS1234717-02 0.02 mg (Yeast)
Recombinant Actinobacillus pleuropneumoniae serotype 7 Acetyl-coenzyme A carboxylase carboxyl transferase subunit alpha (accA)
Ask
View Details MBS1234717-03 0.1 mg (E-Coli)
Recombinant Actinobacillus pleuropneumoniae serotype 7 Acetyl-coenzyme A carboxylase carboxyl transferase subunit alpha (accA)
Ask
View Details MBS1234717-04 0.1 mg (Yeast)
Recombinant Actinobacillus pleuropneumoniae serotype 7 Acetyl-coenzyme A carboxylase carboxyl transferase subunit alpha (accA)
Ask
View Details